-+ 0.00%
-+ 0.00%
-+ 0.00%

JW Therapeutics Expects Carteyva Unit Manufacturing Costs to Fall More Than 65%

PUBT·11/15/2026 10:18:01
JW Therapeutics Expects Carteyva Unit Manufacturing Costs to Fall More Than 65%
  • JW Therapeutics expects Carteyva unit manufacturing costs to fall more than 65% following cost optimization, supporting positive unit economics.
  • Carteyva's reimbursement price under China's National Reimbursement Drug List will be RMB 288,600, effective January 1, 2027.
  • As the only CAR-T therapy included in the basic list, Carteyva is expected to see substantial patient-volume growth.
  • Covered indications represent approximately 11,000 new eligible patients annually; greater scale and lower manufacturing costs are expected to strengthen unit economics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261115-12413041), on November 15, 2026, and is solely responsible for the information contained therein.